Page 405«..1020..404405406407..410420..»

10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes – Targeted Oncology

Posted: June 22, 2022 at 1:55 am

The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.

Until recent years, cancer treatment revolved around surgery, chemotherapy, and radiation. But the FDA approval of ipilimumab (Yervoy) in 2011 led to a fourth leg of that treatment stool: immunotherapy. This enabled new treatment paradigms, sometimes with shocking levels of success.

The types of immunotherapy treatments available are proliferating, with approved immune checkpoint inhibitors (ICIs) and cellular therapies like chimeric antigen receptor (CAR) T cells as well as other modalities in the research and discovery phases. Some even include more established approaches like vaccines that are being revisited with new information and iterations.

The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy. The Bacillus Calmette-Gurin vaccine, used to prevent tuberculosis for a century, has also been used as an immunotherapy to treat nonmuscle invasive bladder cancer since 1990.1 And rituximab (Rituxan), a monoclonal antibody therapy approved in 1997 for B-cell malignancies, is seen by some as an early immunotherapy as well.2

What many clinicians think of in terms of immunotherapy, however, are treatments targeting CTLA-4 and PD-1/PD-L1 pathways, brought from the bench by James P. Allison, PhD, and Tasuku Honjo, PhD, respectively, leading to a Nobel Prize awarded jointly to them in 2018.3

Immune responses are tightly controlled by T cells, and these T cells have on/off switches that help control their responses, according to Padmanee Sharma, MD, PhD, a professor in the Department of Genitourinary Medical Oncology in the Division of Cancer Medicine and the scientific director of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center in Houston. Previously, she said, clinicians were not aware of the off switches. Allison showed that CTLA-4 was an inhibitory pathway and that by blocking it, the T cells could stay longer to eradicate the tumors.

With 8 ICIs approved for immunotherapy in hematological and solid tumors,4 researchers are not only investigating newer forms of therapy, but also combining them to fi nd more effective and durable treatments and introducing them into earlier lines of treatment (TIMELINE). Current research is also attempting to predict who will respond to which therapy based on current and emerging biomarkers.

Ipilimumab, which kicked off the current era of cancer immunotherapy treatment with FDA approval in 2011, targets CTLA-4 for newly diagnosed or previously treated unresectable or metastatic melanoma.5 Ipilimumab blocks CTLA-4, removing its inhibitory signals. This allows the T cells to activate and launch an immune response to the tumors antigens.

CTLA-4 is basically the fi rst inhibitory pathway that comes up on the T cells, Sharma said. CTLA-4 is a member of an immunoglobulin-related receptor family responsible for some immune regulation aspects of T cells.6 It is thought to regulate T-cell proliferation mostly in lymph nodes, early in an immune response, by having an inhibitory role.7

What ipilimumab really did and what the immune checkpoint inhibitors really did is they opened up this whole different way to approach the immune system, Elizabeth Buchbinder, MD, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts, said. Ipilimumab provided amazing durable responses in patients with melanoma with widely metastatic disease, some of whom were alive 10 years later, she said.

The PD-1 and PD-L1 blockades build on ipilimumabs success. Like CTLA-4, PD-1 is a negative regulator of T-cell immune function, inhibiting the target to increase immune system activation. PD-1 suppresses T cells mostly in the peripheral tissues.7 As of November 2021, 8 ICIs have been approved that target CTLA-4, PD-1, and PD-L1 pathways and treat 18 types of cancer.3

AntiPD-1 inhibitors

The percentage of people who benefi tted from ipilimumab was on the low side, Buchbinder said, with only an 11% response rate and 20% of people doing well long term in clinical trials. With PD-1 inhibition, however, there was approximately a 40% response rate and many more patients doing well long term, as demonstrated in clinical trials. So [PD-1 inhibition is] both far more effective and also less toxic, Buchbinder said.

When choosing an agent in the PD-1 class, we dont need to differentiate them. Theyre all antiPD-1, Sharma explained. There arent any data to indicate that patients will respond any differently to pembrolizumab [Keytruda] vs nivolumab [Opdivo]. The mechanism of action for both drugs [is] exactly the same.

Instead, clinicians should consider the FDA approvals for each drugs indications and combinations. But from a scientific standpoint, theres no distinguishing between [them], Sharma said.

AntiPD-L1 inhibitors

PD-1 and PD-L1 targeting drugs were found to work beyond melanoma and kidney cancer, the early indications for treatments targeting the CTLA-4 pathway, Buchbinder said. That was a huge opening up of this fi eld to all of these other cancers, like lung cancer, head and neck cancer, GI [gastrointestinal] cancer, breast [cancer], and beyond, she said.

Before receiving these immunotherapies, patients may need to show PD-1 or PD-L1 expression, although this may not identify all patients who can benefi t from the treatments. Researchers continue to try to identify additional and better biomarkers to indicate which patients may respond.13

In March, the FDA approved the newest ICI, nivolumab and relatlimab-rmbw (Opdualag), for adult and pediatric patients (12 years and older) with unresectable or metastatic melanoma. 3 Nivolumab is a PD-1 inhibitor, and relatlimab blocks LAG3 proteins on immune cells. It is being tested in a lot of other tumors, Buchbinder noted.

Another target in the discovery phase is T cell immunoglobulin and mucin domain 3, which is a checkpoint receptor expressed by many immune cells and leukemic stem cells.14 It is activated by several ligands and is being tested in different cancer types.

Also in clinical trials are tumor-infiltrating lymphocytes (TIL) that recognize cancer cells as abnormal, entering the tumor to kill the cells. TILs already recognize the targets because they originate from the tumor itself.15 Although they need to be expanded, they are not the same as CAR T cells, which must be engineered to recognize the targets.

In addition, older therapies are experiencing a resurgence, with research underway to make interleukin 2 (IL-2) help cytokines function better. That work is trying to optimize what those cytokines do in the body and the immune system, Buchbinder said. There are so many areas where the goal of the therapy is activation of the immune system.

One of these areas includes a return to vaccines. In earlier vaccine therapy, We had no idea that while we were giving therapy to turn on the cells, we were also rapidly turning off the cells because an on switch will automatically drive an off switch for the immune system, Sharma said. The yin and the yang of the immune response is very important to understand because when the immune response is driven in one direction, it will always try to control itself. With that in mind, newer vaccines might work better if given in combination with an antiCTLA-4, for example, to block the inhibitory pathways, she said.

Vaccines are taking many forms, including the mRNA vaccine used for COVID-19, peptide vaccines that include a tiny bit of protein that is expected to be expressed on the tumor surface, and vaccines constructed from dendritic cells, which stimulate T cells, Buchbinder said.

There are also viral therapies injected directly into tumor vaccines, such as talimogene laherparepvec (Imlygic) approved in 2015 for the treatment of some patients with metastatic melanoma that cannot be surgically removed.16 It is a is a modifi ed herpes virus directly injected into the tumor to bring about a local immune response, Buchbinder said.

According to Sharma, approximately 60 targets are currently being evaluated for immunotherapy development.

The FDA has approved 2 CAR T-cell therapies, both in 2017: tisagenlecleucel (Kymriah) for patients 25 years and younger with relapsed B-cell precursor acute lymphoblastic leukemia17 and axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with large B-cell lymphoma that is refractory to fi rst-line chemoimmunotherapy or that relapses within 12 months of fi rst-line chemoimmunotherapy.18 These treatments involve collecting T cells from the patient and engineering them to express CARs that recognize the patients cancer cells. The cells are then enlarged and infused back into the patient, where they can target the antigen- expressing cancer cells. CARs have been shown to greatly improve clinical response and disease remission in some patients.19

I think CAR T cells are clearly building on the concept that T cells are the soldiers of immune response. They are basically engineering the cell to have an antibody that recognizes a specifi c antigen, Sharma said, adding that its important to ensure the targeted antigen is part of the cancer.

CAR T cells have had limited effectiveness in treating solid tumors, given the low T-cell infiltration and immunosuppressive environment that challenges the immune system from successfully reaching and killing solid tumor cancer cells.20

Natural killer (NK) cells are another cell type being researched to attempt tumor eradication, and this therapy is in the early stages, according to Sharma. CAR NK cells can be generated from allogenic donors, making them more attractive as off the shelf treatments compared with CAR T cells, which are collected from the patient. As of early 2021, more than 500 CAR T-cell trials and 17 CAR T-cell/NK-cell trials were in the works globally.21

A major consideration when choosing any treatment, including immunotherapies, is the adverse event (AE) profile. Immunotherapy drugs have different AEs than oncology treatments like chemotherapy or radiation. [With immunotherapy,] what we see is infl ammation because youre turning on the immune system in such a powerful way, Sharma said. Inflammatory reactions include a skin rash or dermatitis, infl ammation in the colon (colitis and diarrhea), and/or infl ammation in the lung with pneumonitis. Clinicians are now aware of these AEs and can monitor them closely, stopping therapy if needed to control them before they become severe, Sharma said.

Toxicities with ipilimumab can be severe, and patients requiring hospital admission might need high-dose steroids, Buchbinder noted. Common AEs for the CTLA-4 inhibitor are typically GI related, including diarrhea, colitis, and hepatitis. Some patients may experience fatigue or a small rash, but most generally make it through treatment with minimal AEs.

The stronger AEs with ipilimumab can be seen from a trial comparing ipilimumab plus nivolumab to nivolumab and relatlimab. Almost 60% of patients experienced AEs with the ipilimumab combination vs 20% in the latter group.17

PD-1 and PD-L1 inhibition typically involve AEs that cause lung issues rather than GI. The types of organ systems affected by immunotherapy AEs can vary based upon which checkpoint inhibitor you use but in some ways, the mechanism by which these occur is very similar, Buchbinder said. Its all an overactivation of the immune system leading to infl ammation in an organ, and there are very few organs that we have not seen toxicity from immunotherapy.

Buchbinder noted that cellular therapies can cause more severe AEs, such as cytokine release syndrome (CRS). Patients can get very sick very quickly, she said, because the therapies given with the cellsincluding the chemotherapy given before and the IL-2 given aftercause most of the AEs. With a lot of the injection therapies, the AEs are related to delivery method, like injection-site issues, but there are also potential systemic AEs like fever, chills, and reactions someone would get to a virus. Its really a huge range in terms of the different [adverse] effects, Buchbinder said.

CRS is the most common AE of CAR T-cell therapy, and it is caused by large numbers of T cells activating, which releases inflammatory cytokines. Although this demonstrates that the therapy is working, it can cause worrisome symptoms. The CRS and the related neurotoxicity can be treated with tocilizumab (Actemra).

One question in the immunotherapy world is whether the development of immune-related AEs predicts a positive or negative response to treatment. With melanoma, we think the data have been very tricky, Buchbinder said. Early trials appeared to show a higher response rate for patients who developed severe symptoms, but as trials developed, that signal was not always there. I think the overall impression is that yes, severe AEs are associated with a better response, she said. A cosmetic AE that clinicians who treat melanoma are excited to see, she said, is vitiligo. It suggests that the immune system is attacking normal melanocytes and that it is attacking cancer cells as well. Those patients generally do far better than patients who dont get vitiligo.

A meta-analysis of 30 studies on the topic, including 4971 individuals, showed that patients who developed immune-related AEs experienced an overall survival benefi t and a progression-free survival benefi t using ICI therapy compared with those who did not. The authors stated that more studies are needed and that the results are controversial.22

Melanoma has been the proving ground for ICIs, Buchbinder said, But now the bar is higher in terms of immunotherapy.

ICIs are now being tested in more immuneresistant tumors. Although there are huge hurdles in terms of some cancers where its going to be hard for immune therapy to do muchlike pancreatic cancer or prostate cancerthere are still diseases where theres opportunity and a possibility that the correct approach or combination might get to some great therapy for those diseases, Buchbinder said

Immunotherapies are being combined with conventional therapies to better integrate treatment. We dont see cancer as a death sentence anymore, Sharma said. We really do see a lot of hope, [and patients with cancer] should be encouraged to discuss immunotherapy with their physician either in a clinical trial or an FDA-approved agent. If you do have a response, its a pretty phenomenal response.

REFERENCES:

1. Lobo N, Brooks NA, Zlotta AR, et al. 100 years of Bacillus Calmette- Gurin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18(10):611-622. doi:10.1038/s41585-021-00481-1

2. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the worlds fi rst oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. doi:10.3389/fonc.2018.00163

3. Kruger S, Ilmer M, Kobold S, et al. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38(1):268. doi:10.1186/s13046-019-1266-0

4. Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022;22(1):e2. doi:10.4110/in.2022.22.e2

5. FDA approves Yervoy (ipilimumab) for the treatment of patients with newly diagnosed or previously-treated unresectable or metastatic melanoma, the deadliest form of skin cancer. News release. Bristol Myers Squibb. March 25, 2011. Accessed May 11, 2022. https://bit.ly/3PFp7q2

6. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58-67. doi:10.1182/ blood-2017-06-741033

7. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98-106. doi:10.1097/COC.0000000000000239

8. Keown A. Keytruda approvals: a timeline. BioSpace. Aug 13, 2019. Accessed May 11, 2022. https://bit.ly/3yHvfrL

9. Stewart J. Opdivo FDA approval history. Drugs.com. Updated March 15, 2022. Accessed May 20, 2022. https://bit.ly/3lnmtar

10. Markham A, Duggan S. Cemiplimab: fi rst global approval. Drugs. 2018;78(17):1841-1846. doi:10.1007/s40265-018-1012-5

11. FDA grants accelerated approval to dostarlimab-gxly for dMMr endometrial cancer. FDA. Updated April 22, 2021. Accessed May 20, 2022. https://bit.ly/38BSJns

12. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the worlds first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. doi:10.3389/fonc.2018.00163

13. Opdualag becomes fi rst FDA-approved immunotherapy to target LAG-3. National Cancer Institute. April 6, 2022. Accessed May 11, 2022. https://bit.ly/3FZWaAp

14. Acharya N, Sabatos-Peyton C, Anderson AC. TIM-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911. doi:10.1136/jitc-2020-000911

15. Boldt C. TIL Therapy: 6 things to know. MD Anderson Cancer Center. April 15, 2021. Accessed May 11, 2022. https://bit.ly/3wmguJb

16. FDA approves talimogene laherparepvec to treat metastatic melanoma. National Cancer Institute. November 25, 2015. Accessed May 20, 2022. https://bit.ly/3woTDwA

17. OLeary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035

18. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. News release. FDA. Oct. 18, 2017. Accessed May 11, 2022. https://bit.ly/3wpECL1

19. FDA approves fi rst CAR T-cell therapy the evolution of CAR T-cell therapy. Cell Culture Dish. October 24, 2017. Accessed May 10, 2022. https:// bit.ly/3LlDD2B

20. Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28:513-527. doi:10.1038/s41434-021-00246-w

21. Ahmad A, Uddin S, Steinhoff M. CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. Int J Mol Sci. 2020;21(11):3906. doi:10.3390/ijms21113906

22. Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? a systematic review and meta-analysis. BMC Med. 2020;18(1):87. doi:10.1186/s12916-020-01549-2

View original post here:
10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology

Posted in Cell Therapy | Comments Off on 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes – Targeted Oncology

New McKinsey center helps clients build capabilities in cell and gene therapy technology – McKinsey

Posted: June 22, 2022 at 1:55 am

June 16, 2022One of New Jerseys fastest-growing industries is life sciences. Already home to some of the worlds largest biopharma companies, the state is now also home to our newest Digital Capability Center. Dedicated to life sciences with a focus on cell and gene therapies, the center was developed in partnership with the New Jersey Innovation Institute and is operated by BioCentriq.

McKinsey operates 12 such facilities globally. Theyre immersive learning environments where people can develop new skills by experimenting with digital technologies, explore new ways of working that will be critical to success, and plan the transformation of their operations both within and beyond their own walls.

Cell and gene therapies are next-generation treatments for a number of diseases. Whereas traditional medicines often require repeated dosages, sometimes with negative side effects, these new therapies are individualized to the patient, offering potentially permanent benefits. In lay terms, cell and gene therapies restore, alter, or replace cells or genes in the body to prevent, treat, and sometimes cure diseasessome of which were previously incurable. Often, they are effective in a single dose.

Live the change

Twenty-three gene therapies have been FDA-approved with promising results for treating diseases including blood cancers, hemophilia, congenital blindness, and spinal muscular atrophy, which is the leading genetic cause of death in infants.

Five years ago these treatments were really just ideas being tested in very small clinical trials, explains McKinsey partnerKatie Kelleher, who along with partnerAndrea Gennari and a team of experts established the center. Now they are the fastest-growing area in therapeutics, and the industry is beginning to commercialize them. But they are very laborious, complex, and expensive to produce and many businesses arent ready to do this.

This is where the new Digital Capability Center can help. As life-sciences companies everywhere are under pressure to hire talent and grow quickly, while improving quality and reliability, says Andrea, we can help them upskill people in operational excellence and transform their use of technology to enable new performance highs.

By using virtual reality technologies, operators can train people on new procedures without requiring the actual equipment or supervisors, who can focus on production.

In particular, the new facility simulates the autologous CAR-T manufacturing process, a therapy used to treat cancer. In it, cells are taken out of a patient at a hospital, transported to a lab where they are purified and modified, and then injected back into that same patient.

Its a complicated, weeks-long process requiring highly skilled technicians, explains Emily Simon, a McKinsey solution manager. For example, the cells have to be frozen in liquid nitrogen during transportation to ensure stasis. A variety of demos in the lab show how digital technologies can improve effectiveness at different points of the process. One use case focuses on how to optimize yield through advanced analytics, which can increase output through more productive cell growth or greater cell viability in the lab.

Hundreds of factors can influence yield, says Emily. From the attributes of the raw materialsthe serums and buffers that contain your cellsto the health of the patient who produced the cells, to factors of the process itself: temperature, pH, oxygen level. Predictive modelling using advanced analytics can help a lab technician forecast potential issues, identify root causes, and identify the ideal conditions for growing new replacement cells.

When you see the digital technologies brought to life, you can truly grasp their full potential.

In another use case, augmented- and virtual-reality technologies help train lab technicians in fundamental skills, such as changing cell-culture media. They can also be used to provide a refresher course for complex processes by practicing first with a virtual version of the equipment; this allows equipment and operators to stay focused on the actual production.

The programs range from half-day workshops for leaders showcasing what the future could be to intensive four-day problem-solving, skill-building classes for teams undertaking a complete transformation.

The center has already hosted several clients, creating moments of insight and impact that perhaps can only be realized in this cutting-edge, hands-on environment. When you see the digital technologies brought to life, a recent participant observed, you can truly grasp their full potential.

Link:
New McKinsey center helps clients build capabilities in cell and gene therapy technology - McKinsey

Posted in Cell Therapy | Comments Off on New McKinsey center helps clients build capabilities in cell and gene therapy technology – McKinsey

Joan Merriam: Prevention is the best medicine – The Union

Posted: June 22, 2022 at 1:54 am

We all know that heart-sinking feeling when our dog gets ill or injured or has a sudden emergency. But lets step backward in time before that illness or accident, and take a look at ways it might have been prevented.

Too many of us dont think a lot about preventive care; instead, we only take action when our dog is clearly sick, badly injured, or due for a vaccination. But thats backward-looking care, when we should be looking forward.

One of the most important preventative steps is to take your dog for annual veterinary checkups. (If your pup is a senior, you should be looking at vet visits twice a year, since older dogs are more likely to suffer from life-threatening health issues like cancer, heart problems, or kidney disease. Theyll also help you catch age-related problems such as hearing or vision loss, cognitive issues, arthritis, and obesity before they become acute.)

Comprehensive veterinary exams can also give you an opportunity to have a frank discussion with your vet about your dogs lifestyle, activity level, mental health, life stage, and behavioral questions. Talk too about what vaccinations and preventative medications are essential for our specific area, and which ones you can skip. For instance, because Lyme disease is endemic in Nevada County, many vets recommend annual Lyme boosters. Another example is heartworm: because this disease can be fatal, its crucial that your dog begins and stays on heartworm preventative for her entire life. Your vet can also help you decide when to spay and neuter your dog, and can do routine procedures like checking to make sure his microchip is scanning properly. (Your dog IS microchipped, isnt he?)

Another prevention suggestion that you may not have thought about is keeping your dogs toenails trimmed. A too-long toenail can easily get snagged, resulting in a painful, torn nail.

Remember that many potential problems can be alleviated if your dog understands basic commands like sit, come, stay, and leave it. These commands arent just a matter of good manners: they can literally save your dogs life if he gets away from you and starts to dart into the road, or puts something dangerous in his mouth.

In the car, always secure your dog with a harness and dog seatbelt, or in a crate or carrier thats strongly fastened in the car. Never let your dog be untethered or uncrated in the open bed of a pickup truck. (In fact, its illegal in California to have an untethered dog in the back of a pickup.) And speaking of cars, remember to NEVER leave your dog alone in a parked car during warm weather unless youve taken strong precautions to keep him cool. Ill talk about some of these ideas in a future column.

Make sure your yard is secure: check your fencing regularly for things like holes, downed sections, and areas where your dog could scoot underneath and get out. Make sure any gates cant be opened by a curious or rowdy dog. Reliable fencing also prevents other animals from getting in and initiating a fight, or in the case of wild animals, badly injuring your dog. And dont rely on so-called invisible or electronic fencing: while it may keep your dog contained (or it may not: many a dog has broken through the electronic barrier and either disappeared or been hit by a car), it wont keep other dogs or animals from coming into your yard and potentially attacking your dog.

Keep all medications out of reach of your dog. Particularly deadly are meds like beta blockers, ACE inhibitors, and ADD/ADHD medications. Even common over-the-counter meds like ibuprofen, acetaminophen, and naproxen can cause serious and even fatal effects if your pup ingests them. And something you think of as harmless like a multivitamin or nasal decongestant can also cause serious health problems for your dog.

The same is true for dog treats, or any type of food your dog might find tasty. Dont assume that your dog probably cant reach a counter or table, or get into a bag of chocolate chips. Most of the time, gorging on a half-full bag of dog cookies will only result in a bout of vomiting or diarrhea, but theres a chance it could trigger a potentially deadly condition like pancreatitis or bloat.

Try to brush your dogs teeth. Dogs can suffer from dental problems just as humans can, and the problems it can cause arent restricted to only their teeth: the bacteria created by periodontal disease can enter the bloodstream and travel to areas like the heart, the liver, and the kidneys. If your dog absolutely refuses to let you get anywhere near him with a toothbrush, try a dog chew specifically made to address plaque and tartar buildup. There are several on the market, but some are more effective than others, so talk with your veterinarian about what she recommends.

So remember: prevention really IS the best medicine!

Joan Merriam lives in Nevada County with her Golden Retriever Joey, her Maine Coon cat Indy, and the abiding spirit of her beloved Golden Retriever Casey in whose memory this column is named. You can reach Joan at joan@joanmerriam.com. And if youre looking for a Golden, be sure to check out Homeward Bound Golden Retriever Rescue

Originally posted here:
Joan Merriam: Prevention is the best medicine - The Union

Posted in Preventative Medicine | Comments Off on Joan Merriam: Prevention is the best medicine – The Union

Prevention is the best medicine | Caseys Corner – Oroville Mercury-Register

Posted: June 22, 2022 at 1:54 am

We all know that heart-sinking feeling when our dog gets ill or has a sudden emergency. But lets step backward in time before that illness or accident, and take a look at ways it might have been prevented.

Too many of us dont think a lot about preventive care; instead, we only take action when our dog is clearly sick, badly injured or due for a vaccination. Thats backward-looking care, when we should be looking forward.

One of the most important preventative steps is to take your dog for annual or semi-annual, if your pup is a senior veterinary checkups. These comprehensive exams can catch little problems before they become big ones. They also give you an opportunity to have a frank discussion with your vet about your dogs lifestyle, activity level, mental health, life stage and behavioral issues. Talk too about what vaccinations and preventative medications are essential for your specific area, and which ones you can skip. Your vet can also help you decide when to spay and neuter your dog and can do routine procedures like checking to make sure his microchip is scanning properly. (Your dog is microchipped, isnt he?)

Another prevention suggestion that you may not have thought about is keeping your dogs toenails trimmed. A too-long toenail can easily get snagged, resulting in a painful, torn nail.

In the car, always secure your dog with a harness and dog seatbelt, or in a crate or carrier thats strongly fastened in the car. Never let your dog be untethered or uncrated in the open bed of a pickup (In fact, its illegal in California to have an untethered dog in the back of a pickup).

Make sure your yard is secure: check your fencing regularly for things like holes, downed sections and areas where your dog could scoot underneath and get out. Make sure any gates cant be opened by a curious or rowdy dog. Reliable fencing also prevents other animals from getting in and initiating a fight, or in the case of wild animals, badly injuring your dog. And dont rely on so-called invisible or electronic fencing: While it may keep your dog contained (or it may not: many a dog has broken through the electronic barrier and either disappeared or been hit by a car), it wont keep other dogs or animals from coming into your yard and potentially attacking your dog.

Keep all medications out of reach of your dog. Even common over-the-counter meds like ibuprofen and naproxen can cause serious and even fatal effects if your pup ingests them. The same is true for dog treats, or any type of food that your dog might find tasty. Dont assume that your dog probably cant reach a counter or table or cant get into a bag of chocolate chips. Most of the time, gorging on a half-full bag of dog cookies will only result in a bout of vomiting or diarrhea, but theres a chance it could trigger a potentially deadly condition like pancreatitis or bloat.

Try to brush your dogs teeth. Dogs can suffer from dental problems just as humans can, and the problems it can cause arent restricted to only their teeth: the bacteria created by periodontal disease can enter the bloodstream and travel to areas like the heart, the liver and the kidneys. If your dog absolutely refuses to let you get anywhere near him with a toothbrush, try a dog chew specifically made to address plaque and tartar buildup. There are several on the market, but some are more effective than others, so talk with your veterinarian.

So remember: prevention really IS the best medicine!

Joan Merriam lives in Nevada County with her golden retriever Joey, her Maine coon cat Indy and the abiding spirit of her beloved golden retriever Casey in whose memory this column is named. You can reach Joan at joan@joanmerriam.com. And if youre looking for a golden, be sure to check out Homeward Bound Golden Retriever Rescue.

See the rest here:
Prevention is the best medicine | Caseys Corner - Oroville Mercury-Register

Posted in Preventative Medicine | Comments Off on Prevention is the best medicine | Caseys Corner – Oroville Mercury-Register

RIVERVIEW PRIMARY CARE PROVIDERS AVAILABLE TO OVERSEE YOUR HEALTH NEEDS – kroxam.com

Posted: June 22, 2022 at 1:54 am

If you do not already have a primary care provider, summer is a great time to establish a relationship with a professional to guide you on your health care journey.

RiverView Health has various primary care providers specializing in Family Medicine and Internal Medicine. A primary care provider (PCP) should be the first person in the healthcare system that you contact when you are sick or have a question about your health. They can provide care and answers to your questions or recommend a specialist to meet your needs.

If a specialist is needed, your PCP will work to coordinate information between all of your healthcare providers. That provider will also ensure there is no duplication of care and testing and that nothing is left out. Your provider can also help you find other resources, such as support groups and classes.

Preventative Care

One of the primary responsibilities of a PCP is to provide preventative care. A PCP can help you catch problems before they arise. Your provider will get to know you, your history, and your family history. They will ensure you get necessary screenings and identify and treat any minor problems before they become major ones.

It is important that you build an honest relationship with your PCP. While it can be intimidating and embarrassing to openly discuss your health concerns, discussing even the most personal health problems is important. Remember that your provider will not be embarrassed, shocked, or offended by even your most embarrassing symptoms.

Play an active role in your health. Make sure you speak up with any questions or concerns about your health, regardless of how minor they may seem. Take your providers warnings seriously, and do not hesitate to ask for more informational resources.

The easiest way to prolong life and keep healthcare costs affordable for everyone is to take measures to prevent illness whenever possible. Annual exams and a healthy lifestyle are two great preventative measures you can control. At the same time, a competent PCP offers the continuity of care that health maintenance over a lifetime requires.

RiverView Health has primary care providers in Crookston, Fertile, and Red Lake Falls. Choose the provider who best suits your needs and knows that you are not alone in your lifetime journey of good health for you and your family.

Family Medicine

RiverView Clinics offer a wide variety of Family Medicine providers including medical doctors (MD), a Doctor of Osteopathic Medicine (DO), certified nurse practitioners (CNP), family nurse practitioners certified (FNP-C), and physician assistant (PA). Family Medicine providers care for people of all ages from infants through end-of-life. These providers often care for the same patients throughout their lives, and in many cases, they care for multiple generations of family members simultaneously.

Family Medicine providers at RiverView Health and their practice locations include:

Internal Medicine

Internal Medicine providers, also called internists, care primarily for adults. Internal medicine doctors specialize in diagnosing, treating, and preventing disease in their adult patients. They offer care for a wide variety of health conditions and counsel their patients on prevention and overall wellness.

The following Internal Medicine doctors offer primary care at RiverView:

If seeing a PCP during regular office hours does not fit into your schedule, RiverViews certified nurse practitioners and family nurse practitioners offer early and late appointments at Crookstons extended hours clinic, which is open Monday through Friday, 7:00 a.m. to 7:00 p.m., and weekends from 9:00 a.m. to 1:00 p.m.

All RiverView Health providers are taking new patients. To schedule an appointment with any of the providers listed above, call 281-9595 and ask for an appointment to establish care with the provider of your choice or ask the patient access representative for options.

Originally posted here:
RIVERVIEW PRIMARY CARE PROVIDERS AVAILABLE TO OVERSEE YOUR HEALTH NEEDS - kroxam.com

Posted in Preventative Medicine | Comments Off on RIVERVIEW PRIMARY CARE PROVIDERS AVAILABLE TO OVERSEE YOUR HEALTH NEEDS – kroxam.com

With Father’s Day in mind, Mayo Clinic doctors remind men to be mindful of their health – WQOW TV News 18

Posted: June 22, 2022 at 1:54 am

(WQOW) - With Father's Day in mind, Mayo Clinic wants men to be mindful of their health.

Men are sometimes uncomfortable seeing a doctor for their medical issues, but health officials with Mayo say that some of the best medicine is preventative medicine.

Dr. Tobias Kohler said that sometimes problems with erections are early indicators of other cardiovascular issues, and could predate a heart attack or stroke.

"It's one of the many examples of how some problems can tell us more information than just that individual structure. That's why it's so important to go in and be checked as we age," he said.

Health officials also talked about the importance of prostate cancer screenings. Dr. Jeff Karnes said early detection can potentially save men from severe symptoms, and ultimately increase their chances of survival. Prostate cancer is the second leading cancer cause of death in men in the U.S.

Karnes said while some men don't have symptoms with prostate cancer, there are symptoms to look out for.

"Some things that I think men should seek immediate attention for is a sudden change in urination, and symptoms that could be attributed to an urinary tract infection," he said.

Both doctors say that even though some men are uncomfortable going to the doctor unless absolutely necessary, getting screened for these illnesses can save a life.

Have a story idea? Let us know here

Link:
With Father's Day in mind, Mayo Clinic doctors remind men to be mindful of their health - WQOW TV News 18

Posted in Preventative Medicine | Comments Off on With Father’s Day in mind, Mayo Clinic doctors remind men to be mindful of their health – WQOW TV News 18

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and…

Posted: June 13, 2022 at 2:42 am

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, Editas Medicine), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicines CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institutes Cas9 patent estates and Broad Institutes Cas12a patent estate for human medicines.

By combining Editas Medicines gene editing technology with Immatics ACTallo allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, gamma-delta T cells can be redirected to cancer cell targets with the goal of creating cells with enhanced tumor recognition and destruction.

Engineered cell therapies have the potential to significantly impact the treatment paradigm for cancer, and our partnership with the esteemed team at Editas Medicine will provide us with further versatility and flexibility in how we engineer our ACTallo cell therapies based on a specific tumor target, said Rainer Kramer, Ph.D., Chief Business Officer, Immatics. It has always been our focus to deliver innovative science to cancer patients and this collaboration with Editas Medicine will enable us to access CRISPR technologies and apply them to our off-the-shelf gamma-delta T cell platform.

We believe that our gene editing technology can modulate and enhance the potential of cell therapies to deliver transformative medicines for the treatment of cancer. We are excited to work with the team at Immatics to develop new experimental medicines with enhanced tumor fighting abilities to help patients with cancer, said Gilmore ONeill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.

Under the terms of the agreement, Editas Medicine will be eligible to receive an undisclosed upfront cash payment as well as additional milestone payments based on development, regulatory, and commercial milestones. In addition, Immatics will pay royalties on future net sales on any products that may result from this collaboration.

About ImmaticsImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Instagram, Twitter and LinkedIn.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Harvard and Broad Institutes Cas9 patent estates and Broad Institutes Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

Immatics Forward-Looking StatementsCertain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Editas Medicine Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, target, should, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the expected benefits of Editas Medicines collaboration with Immatics, including any future payments it may receive under the strategic research collaboration and licensing agreement and the potential to generate medicines from the collaboration. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of Editas Medicines product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicines foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in Editas Medicines most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by Editas Medicines subsequent filings with the Securities and Exchange Commission, and in other filings that Editas Medicine may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent Editas Medicines views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Editas Medicine explicitly disclaims any obligation to update any forward-looking statements.

Source: Editas Medicine, Inc.

See the original post here:
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and...

Posted in Cell Medicine | Comments Off on Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and…

ASCO 2022: Gilead’s tough weekend, bispecific progress and ‘gamma delta’ cell therapy – BioPharma Dive

Posted: June 13, 2022 at 2:42 am

For years, the American Society of Clinical Oncologys annual meeting has served as the main forum for advances in cancer immunotherapies like Merck & Co.s Keytruda and Bristol Myers Squibbs Opdivo.

While new data continue to emerge for those drugs and their competitors, this years conference was headlined by dramatic data for another type of cancer medicine from AstraZeneca and Daiichi Sankyo, which put pressure on rival Gilead. And with CAR-T therapies now established, attention has shifted to other emerging approaches for training the immune system to attack tumors.

Read on for updates on Gilead, bispecific antibodies for blood cancer and gamma delta cell therapy.

ASCO is an important conference for any biotech developing a cancer drug. But this years meeting was particularly so for Gilead, which has spent a decade and billions of dollars trying to build its oncology business. Analysts and investors were eagerly awaiting the details of a key study of the breast cancer drug Trodelvy, for which it paid $21 billion to acquire last year. Updates were also expected for magrolimab, another cancer medicine Gilead recently bought in a large deal.

The drugs either underwhelmed or were upstaged by others, however. Trodelvy led to a 1.5-month improvement over chemotherapy on a measure of tumor progression in a late-stage study of patients with a common form of metastatic breast cancer. The result fell short of the 2-month target doctors surveyed by analyst firm RBC Capital Markets felt would warrant meaningful use, according to a research note.

Trodelvy was also overshadowed by AstraZeneca and Daiichi Sankyos rival breast cancer drug, Enhertu, whose data in so-called HER2 low tumors were so striking they received a standing ovation at the meeting.

All the enthusiasm for Trodelvy has evaporated after those results, wrote Baird analyst Brian Skorney in a note on Sunday, adding that Enhertus likely approval in HER2 low breast cancer could limit Trodelvys revenue potential.

Analysts were similarly unimpressed by the latest data for magrolimab, a blood cancer drug that was slowed by safety concerns this year. Initial data showed a response rate of 50% for a combination of magrolimab and the chemotherapy azacitidine in an early-stage trial in myelodysplastic syndrome. That rate has fallen to 33% with additional data, barely surpassing whats been observed in tests of chemotherapy alone, Skorney wrote.

Complete response rates slipped in a Phase 1 acute myeloid leukemia study as well. The updates show Gileads drug has sufficient activity, though its perhaps not the home run it was initially hoped to be, wrote RBC analyst Brian Abrahams in a note to clients.

Gilead will likely need to show more before investors view the cancer portfolio as a major growth driver, Abrahams added. Shares ticked down 2% in early Monday trading.

The biotech did get a reprieve on Friday, however, announcing that regulators had lifted their last remaining hold on studies of magrolimab in lymphoma and multiple myeloma.

Cell therapy has become a powerful new treatment option for blood cancers like lymphoma and multiple myeloma. Approved drugs from Gilead, Bristol Myers Squibb, Novartis and Johnson & Johnson use souped-up immune cells genetically modified and infused back into patients to attack cancers.

But the approach, while potent, involves a painstaking manufacturing process that requires physicians to carefully time treatment. In multiple myeloma, Bristol Myers and J&J have struggled to keep up with demand, Stat News has reported, further complicating cell therapy's use.

While drugmakers expect to overcome those hurdles with time, they are busy advancing other ways to redirect immune cells to target cancer. One alternative uses an antibody to latch onto protein flags found on the surface of immune cells and their cancerous targets, bringing them into tumor-killing contact.

These so-called bispecific antibodies have already shown promise in some of the same blood cancers addressed by CAR-T cell therapies. At ASCO, Roche and J&J revealed updated clinical trial data supporting their respective medicines for lymphoma and multiple myeloma. AbbVie and partner Genmab, meanwhile, will present data on their lymphoma bispecific antibody at the European Hematology Association's meeting next weekend.

Scott Gottlieb, formerly Food and Drug Administration commissioner and currently a member of Pfizers board, pointed to bispecific antibody data as some of the most exciting to come out of ASCO this year.

"That data looks very promising," he said on CNBCs Squawkbox program Monday, noting the therapies from Roche and partners AbbVie and Genmab specifically.

Specifically, Roche's data showed treatment led to responses in half of patients with relapsed or refractory diffuse large B-cell lymphoma who were treated in the study. Nearly 40% went into remission.

Notably, about a third of the 154 participants had previously received CAR-T therapies, which have recently been approved in the U.S. for earlier use in treating advanced lymphoma.

"We still need longer follow-up for the bispecific antibodies," said Kerry Savage, a medical oncologist at The University of British Columbia, who discussed Roche's abstract at ASCO on Friday. "We don't know the curative potential yet, but it's certainly encouraging so far."

AbbVie and Genmab's results, which will be presented on Saturday at EHA, showed a slightly higher overall response rate of 63% and a similar remission rate of 39% among adults with several variations of relapsed or refractory large B-cell lymphoma.

J&J, meanwhile, brought updated data to ASCO for its multiple myeloma bispecific teclistamab, which were also published in The New England Journal of Medicine. The data showed treatment could beat back cancer and, in about 40% of patients, lead to remission.

"The high rate of deep and durable responses in this population indicates the potential for teclistamab to provide substantial clinical benefit to a broader population of patients," researchers wrote in NEJM.

The search for more convenient alternatives to personalized cell therapies has led to other off-the-shelf strategies besides bispecific antibodies. One emerging approach involves gamma delta T cells, rare white blood cells that can recognize a range of targets.

Adicet Bio, In8Bio, Immatics, among others, are developing treatments and multiple large companies have shown interest in their work. Bristol Myers Squibb just last week expanded an existing deal with Immatics, while Takeda and Johnson & Johnson have recently made investments, too.

Adicets program, a potential treatment for non-Hodgkins lymphoma, is the most advanced of the group, making its trial results an important proof point for the field.

Prior to the meeting, Adicet said four of six treated patients with a low or medium dose went into remission, with two of the three patients treated still cancer free after three months. Importantly, there were no serious immune or neurological side effects reported.

At ASCO, Adicet disclosed results from two additional patients as well as longer follow-up from others. While early, the findings are in the range with CAR-T therapy. As of May 31, six of eight patients including two at the highest tested dose had responded to treatment. All six initially went into remission.

Notably, these were heavily pretreated patients, three of whom whose disease had progressed after CAR-T. Adicet hasnt reported any cases of severe cytokine release syndrome, a common side effect of CAR-T.

Yet the treatments durability remains in question. Though four of the complete responses are ongoing, only one has lasted longer than six months. One patient previously in remission died from COVID-19, while another relapsed.

Adicet plans to pick a dose to advance into further testing. The company amended its trial to include a higher dose as well as potentially evaluate a multiple-dose regimen, a strategy other off-the-shelf cell therapy developers are testing as well.

Go here to see the original:
ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy - BioPharma Dive

Posted in Cell Medicine | Comments Off on ASCO 2022: Gilead’s tough weekend, bispecific progress and ‘gamma delta’ cell therapy – BioPharma Dive

Dr Swaminathan P. Iyer on Efficacy, Safety of CD70-Targeted CAR T-Cell Therapy in R/R T-Cell Lymphoma – AJMC.com Managed Markets Network

Posted: June 13, 2022 at 2:42 am

An acceptable safety profile and durable complete response (CR), partial response (PR) rates were observed with the chimeric antigen receptor (CAR) T-cell therapy CTX130 in the phase 1 COBALT-LYM study of patients with relapsed/refractory T-cell lymphomas, said Swaminathan P. Iyer, MD, professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center.

Iyer served as lead author of a study presented today at the 2022 European Hematology Association (EHA) Congress, titled, "The COBALT-LYM Study of CTX130: A Phase 1 Dose Escalation Study of CD70-Targeted Allogeneic CRISPR-Cas9Engineered CAR-T Cells in Patients with Relapsed/Refractory (R/R) T-cell Malignancies.

Transcript

What is the mechanism of action for CTX130 in T-cell lymphoma, and can you discuss how the COBALT-LYM study was conducted?

So, CTX130 is a first-in-class allogeneic CAR T-cell for T-cell lymphomas. And the study that put together this CAR T was called the COBALT-LYM study, and the target here is CD70, [which] is a protein that is expressed on the surface of cells. It's been found that 85% of T-cell lymphomas express them.

A lot of investigations of the past have been done on CD70 in terms of antibodies and antibody drug conjugates. What's different about this construct, it's an allogeneic CAR T, which means healthy donors are selected and the chimeric antigen receptor is created using CD70 as a construct, and using the other activation and costimulatory domains.

This is the product, CTX130, and this a phase 1 dose-finding study allowable in patients who express at least greater than 10% of CD70 in patients with PTCL [peripheral t-cell lymphoma] and patients with CTCL [transformed cutaneous t-cell lymphoma]. For PTCL, the prior criteria is one prior line of therapy, for CTCL its at least 2 systemic therapies.

The patients were enrolled, and you will see the presentation this afternoon, from the abstract, it's 18 patients data who participated in this study, and 70% overall response rate and 29% CR based on the abstract. So, this is the CTX130, and there's more data that will be presented this afternoon.

Can you discuss efficacy and safety findings reported at EHA2022 of the COBALT-LYM study?

So, the first thing is safety. Since it's a dose-finding study, phase 1, the main goal of part A, which is the dose escalation, is safety. Since it's a CAR T construct, it has certain potential side effects that are very different from other drugs, if you will.

So, the things that you would expect in CAR Ts are cytokine release syndrome [CRS], the neurological toxicity called ICANS [immune effector cell-associated neurotoxicity syndrome], and since its an allogeneic CAR T, GVHD [graft versus host disease], and since it's an effective therapy, tumor lysis syndrome (TLS), and then everything else that other drugs might cause.

So, in this particular study, the safety was acceptable across all those levels4 of those levels tested, 1, 2, 3, and 4, going from 30 to 900 million cells, and the safety was acceptable. The CRS was mostly grade 1 and 2, the neurological toxicity was grade 1 and 2, all of which resolved. There was no TLS, no GVHD.

There were some infections seen. One out of the 4 infections of the grade 3 or higher were attributable to the CAR T, but otherwise, there are other treatment-emergent SAEs [serious adverse events], such as syncope, presyncope, tumor hemorrhagethey were all not deemed related to CTX130. So, safety wise, very acceptable.

Efficacy, I just mentioned 70% overall response rate with 29% CRs. And some of these CRs were durable CRs. You will see that many of them could be bridged to the more longer-term consolidation therapy. But for the first time you're seeing responses in T-cell lymphomas, patients who did not achieve prior responses like a CR, and now we're getting to the point where you have PRs and CRs that are lasting.

Read this article:
Dr Swaminathan P. Iyer on Efficacy, Safety of CD70-Targeted CAR T-Cell Therapy in R/R T-Cell Lymphoma - AJMC.com Managed Markets Network

Posted in Cell Medicine | Comments Off on Dr Swaminathan P. Iyer on Efficacy, Safety of CD70-Targeted CAR T-Cell Therapy in R/R T-Cell Lymphoma – AJMC.com Managed Markets Network

Insights on the Single Cell Sequencing Global Market to 2027 – Ongoing Demand for Personalized or Customized Medicine Presents Opportunities -…

Posted: June 13, 2022 at 2:42 am

DUBLIN--(BUSINESS WIRE)--The "Single Cell Sequencing Market Research Report by Product (Consumables and Instruments), Application, End-User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Single Cell Sequencing Market size was estimated at USD 2,301.59 million in 2021, USD 2,407.37 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.77% to reach USD 3,044.54 million by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Single Cell Sequencing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Single Cell Sequencing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Single Cell Sequencing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Single Cell Sequencing Market?

4. What is the competitive strategic window for opportunities in the Global Single Cell Sequencing Market?

5. What are the technology trends and regulatory frameworks in the Global Single Cell Sequencing Market?

6. What is the market share of the leading vendors in the Global Single Cell Sequencing Market?

7. What modes and strategic moves are considered suitable for entering the Global Single Cell Sequencing Market?

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/nel4wa

More:
Insights on the Single Cell Sequencing Global Market to 2027 - Ongoing Demand for Personalized or Customized Medicine Presents Opportunities -...

Posted in Cell Medicine | Comments Off on Insights on the Single Cell Sequencing Global Market to 2027 – Ongoing Demand for Personalized or Customized Medicine Presents Opportunities -…

Page 405«..1020..404405406407..410420..»